STOCK TITAN

Research Alliance Corp III: Trails Edge holds 9% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Research Alliance Corp III (RACC) was the subject of an amended ownership report stating that Trails Edge Biotechnology Master Fund, LP directly held 822,500 Class A ordinary shares, or 9.0% of the class, as of September 30, 2026. Its investment manager, Trails Edge Capital Partners, LP, and Ortav Yehudai, Chief Investment Officer of Trails Edge Capital Partners, may each be deemed to beneficially own those same shares. Yehudai exercises voting and investment discretion over them.

Class A ordinary shares beneficially owned 822,500 shares Held directly by Trails Edge Biotechnology Master Fund, LP as of September 30, 2026; the other reporting persons may be deemed to own the same shares.
Ownership of class 9.0% As of September 30, 2026.
Ordinary shares issued and outstanding 9,098,529 shares As of October 13, 2026; used as the basis for the ownership percentage.
beneficially own financial
"may be deemed to beneficially own an aggregate of 822,500 Class A Ordinary Shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Sole Voting Power financial
"Sole Voting Power 822,500.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Power financial
"Sole Dispositive Power 822,500.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RACC shares did Trails Edge report?

Trails Edge Biotechnology Master Fund, LP directly held 822,500 Class A ordinary shares as of September 30, 2026, equal to 9.0% of the class. Trails Edge Capital Partners, LP and Chief Investment Officer Ortav Yehudai may also be deemed beneficial owners of those same shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





G75226103

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4 for additional information.


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4 for additional information.


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4 for additional information.


SCHEDULE 13G



Trails Edge Capital Partners, LP
Signature:/s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai
Name/Title:Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
Date:11/16/2026
Trails Edge Biotechnology Master Fund, LP
Signature:/s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai
Name/Title:Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC
Date:11/16/2026
Ortav Yehudai
Signature:/s/ Ortav Yehudai
Name/Title:Ortav Yehudai / Individual
Date:11/16/2026
Exhibit Information

Exhibit 1 - Joint Filing Agreement dated as of May 29, 2026, by and between Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP and Ortav Yehudai (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on May 29, 2026).

Keep reading